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Akta b s t r a c t
CREB binding protein (CBP) is an acetyltransferase that plays an important role in many biological
processes. Here, we show that Akt phosphorylates CBP at threonine 1871 and suppresses its acetyl-
transferase activity by impeding the binding of CBP to histone H3, which results in a decrease in
lysine K18 acetylation and dysregulation of target genes. Our results demonstrate that Akt regulates
acetyltransferase activity through CBP phosphorylation, which may contribute to tumorigenesis.
Structured summary of protein interactions:
CBP physically interacts with AKT1 by anti tag coimmunoprecipitation (View Interaction: 1, 2)
CBP physically interacts with AKT1 by anti tag coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the possibility that different cellular functions that are induced bySince its discovery as an effector of PI3-K (phosphoinositide
3-kinase) [1], the serine/threonine kinase Akt (also known as PKB,
protein kinase B) has emerged as a critical signal transducer of onco-
genic signals in virtually all human solid tumors and hematological
malignancies. Most cancers display elevated Akt activity, and this is
achievedbygrowth factor signalingor throughoncogenicmutations
in the PI3K pathway [2]. PI3K-Akt activation results in phosphoino-
sitide phosphorylation, changes in cell morphology, increased angi-
ogenesis and cell survival [3]. Nearly200Akt substrateproteinshave
been identiﬁed [4–6]. These Akt substratesmost likely contribute to
the diverse cellular roles of Akt, which include cell survival, growth,
proliferation, angiogenesis, metabolism and migration [2].
Epigenetic modiﬁcations, such as histone acetylation and meth-
ylation or DNA methylation, are associated with transcriptional
activities and cellular functions [7]. Aberrant changes in speciﬁc his-
tonemodiﬁcations, such as H3K27methylation (H3K27me) and the
acetylation of H3K9 and H3K56, have been reported in a variety of
human cancers [7–10]. These modiﬁcations often affect chromatin
structure and the subsequent transcriptional activity of genes [7],
including the activity of oncogenes or tumor suppressor genes. A re-
cent study suggested that certain epigenetic modiﬁcations can be
targeted via speciﬁc signaling pathways [11]. This ﬁnding raisedspeciﬁc signaling transduction events may be executed by distinct
epigenetic machinery.
Aberrant changes inhistoneH3acetylationat lysineK18 (H3K18ac)
have been reported in a variety of human cancers [7,8,12,13]. The his-
tone acetyltransferases p300, CBP [14], Gcn5, PCAF [15] and SIRT7 [16]
have been reported to acetylate H3K18. This modiﬁcation process has
been shown to be reversible, and enzymes responsible for acetylation
are known to be involved inmalignancy [17]. For instance, the histone
acetyltransferases (HATs) p300 and CBP have been implicated in the
progression and metastasis of multiple cancer types [17]. However, it
is unclear why four HATs target the same lysine, whether these HATs
are cell type- of context-speciﬁc and whether they are regulated by
speciﬁc tumor signaling pathways.
Our research revealed that the phosphatidylinositol-3-kinase-
Akt (PI3K-Akt) pathway [3] speciﬁcally regulates H3K18ac and
tumorigenesis via CBP but not p300. In addition, we demonstrated
that phosphorylation of CBP (P-CBP) at Thr1871 by Akt enhances
the oncogenic activities of CBP and that H3K18ac levels correlate
with P-Akt and P-CBP in a wide variety of human cancers.
2. Materials and methods
2.1. Reagents and antibodies
Rabbit polyclonal anti-AKT (#9272) and anti-phospho-GSK3b
antibodies (#9336), rabbit monoclonal anti-phospho-Akt (Ser473)
(#4058) antibody and rabbit polyclonal anti-H3 (#9715) antibody
were purchased from Cell Signaling Technology. Rabbit polyclonal
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(ab12188) and anti-Gcn5 (ab18381) antibodies were purchased
from Abcam. Rabbit monoclonal anti-CBP (ab2832) and anti-p300
(ab14984) antibodies were also purchased from Abcam. Mouse
monoclonal anti-b-actin (#TA09), anti-HA-tag (#TA04) and anti-
Myc (#TA01) antibodies were purchased from the Zhongshan
Golden Bridge Biotechnology Company. MTT (#M2128) was pur-
chased from Sigma. Cy3 AfﬁniPure F(ab0)2 Fragment Goat Anti-
Rabbit IgG (H + L) (#111-166-003) was purchased from Jackson
ImmunoResearch. The PI-3K inhibitor LY294002 (#440202) was
purchased from Calbiochem (San Diego, CA). IGF (#13769) was
purchased from Sigma Co. (St. Louis, MO). The antibody against
the phosphorylation site of CBP-T1871 was produced by Beijing
Bohaitongda Bio-Tech Co., Ltd.
2.2. Plasmid construction and siRNA
The coding regions of human Akt and CBP were ampliﬁed from
HeLa cDNA by polymerase chain reaction (PCR). The PCR products
were subcloned into HA-tag or Myc-tag vectors and sequenced.
The mutation plasmids were constructed with the TaKaRa Mutan-
BEST Kit (#D401), as recommended by the manufacturer. siRNAs
were purchased from Shanghai GenePharma.
2.3. Cell viability
The cells (5  103 per well) were seeded in complete DMEM
(100 lL/well) in 96-well plates. Untreated cultures were used as
negative controls. A 20-lL aliquot of MTT (5 mg/ml) was added
to each well, and the plates were incubated at 37 C for 4 h. Follow-
ing this incubation, 100 lL dimethyl sulfoxide was added to each
well to lyse the cells. The absorbance was measured at 570 nm in
a multiwell spectrophotometer (Emax; Molecular Devices, Sunny-
vale, CA).
2.4. Soft-agar colony formation assay
For the soft agar assay, the cells were suspended in DMEM con-
taining 0.35% low-melting agarose. The cells were then plated onto
solidiﬁed 0.6% agarose in DMEM in 6-well culture plates at a den-
sity of 1  103 cells per well. The number of colonies was observed
by microscopy (40) 3 weeks after seeding.
2.5. Transwell migration assay
Cell migration was assayed using a Transwell systemwith 8-lm
pore ﬁlters (Costar, Boston, MA). After ﬁlling the lower chamber
with complete medium, 1  104 cells in 0.5 ml serum-free med-
ium were loaded into the upper chamber. Following 12 h of incu-
bation at 37 C, the cells that migrated to the bottom surface of
the membrane were ﬁxed with methanol, stained with 0.5% crystal
violet and microscopically inspected. The cells on the top surface of
the membrane were removed with a cotton swab. The OD570 of the
cells that had been washed with acetic acid was measured.
2.6. In vivo tumor growth analysis
Cells were injected (2  106 cells) orthotopically into the fourth
mammary fat pad of nude mice (10 mice per group). The tumor
volumes were measured twice weekly, and the data were tested
statistically with a two-sided long-rank analysis.
2.7. Microarray analysis
All of the microarray analyses were performed by CapitalBio
Corporation.2.8. HAT activity assay
In vitro HAT activity was assayed by measuring the amount of
histone acetylated by CBP. A 25 lL reaction mixture containing
Myc-tagged wild type (WT) CBP, T1871E or T1871A mutant,
10 lg histone and 10 lM acetyl-coenzyme A in HAT assay buffer
(50 mM Tris–HCl, pH 8.0, 10% glycerol, 0.1 mM EDTA and 1 mM
dithiothreitol) was incubated at 30 C for 30 min and then sub-
jected to SDS–PAGE for protein separation. Myc-CBP and HA-Akt
were immunopuriﬁed from cell lysates, and the HAT activity of
Myc-CBP phosphorylated by HA-Akt was assayed in the presence
of histone and acetyl coenzyme A. Acetylated histone was analyzed
by Western blotting.
2.9. Chromatin immunoprecipitation (ChIP)
Approximately 3  106 cells per sample were cross-linked for
10 min in 1% formaldehyde at room temperature. The cells were
washed twice with cold PBS and lysed with SDS Lysis Buffer (Up-
state, #20-163). The lysates were sonicated in an ultrasonic bath
(Bioruptor, Diagenode) to shear the DNA to an average length of
200–800 bp. Following sonication, the samples were centrifuged
at 15000g. The supernatants were diluted with ChIP Dilution Buf-
fer (Upstate, #20-153) and immunoprecipitated overnight with
primary antibody at 4 C. The control immunoprecipitations were
performed with 2 lg normal anti-IgG antibody. The beads were
washed sequentially for 5 min each in low-salt (Upstate, #20-
154:20 mM Tris–HCl pH 8, 150 mM NaCl, 2 mM EDTA, 1% Triton
X-100 and 0.1% SDS), high-salt (Upstate, #20-155:20 mM Tris–
HCl pH 8, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1%
SDS) and LiCl buffers (Upstate, #20-156: 10 mM Tris pH 8.0,
1 mM EDTA, 250 mM LiCl, 1% NP-40 and 1% deoxycholate) at
4 C. Finally, the beads were washed twice in 1  TE (Upstate,
#20-157) for 2 min at room temperature. The DNA was eluted
from the beads in 1% SDS/100 mM NaHCO3 for 15 min at room
temperature. NaCl was added to a ﬁnal concentration of 200 mM,
and the crosslinks were reversed for 7 h at 65 C. The eluted DNA
was precipitated with ethanol overnight at 20 C, treated with
20 lg proteinase K and puriﬁed with QIAquick PCR Puriﬁcation
Columns (Qiagen) as recommended by the manufacturer. The
immunoprecipitated DNA (1.5 lL) and serial dilutions of the 10%
input DNA (1:4, 1:20, 1:100 and 1:500) were analyzed by real-time
qPCR. The primer sequences are available upon request.
2.10. In vitro phosphorylation
The immunoprecipitates with anti-Akt or anti-hemagglutinin
(anti-HA) antibody were collected, washed and then incubated at
30 C for 30 min in 20 lL of kinase reaction mixture containing
10 lM [c-32P]ATP and 1 lg of either bacterially expressed GST-
CBP as Akt or immunoprecipitated Myc-CBP as a HA-Akt substrate.
The reaction was terminated by the addition of an equal volume of
Laemmli buffer. Proteins were separated by electrophoresis on 10%
SDS–polyacrylamide gels, and phosphorylated GST fusion proteins
or Myc-CBP were visualized by autoradiography. Myc-CBP and HA-
Akt were immunopuriﬁed from cell lysates, and the phosphoryla-
tion of Myc-CBP by HA-Akt was assessed by Western blotting with
anti-phosphoserine antibody (Chemicon, Temecula, CA) after incu-
bation in the kinase reaction mixture without [c-32P]ATP.
2.11. Co-immunoprecipitation analysis
Cells were harvested, washed with ice-cold PBS, resuspended in
BC300 buffer (20 mM Tris–Cl, pH 8.0, 300 mM NaCl, 0.2 mM EDTA,
10% glycerol, 0.2 mM PMSF and 0.2% Tween-20) and then pulse
sonicated (BRANSON Digital Soniﬁer) 10 times on ice (3 s with
Fig. 1. Akt negatively regulates H3K18ac. Cell lysates of the indicated cell lines
were analyzed by Western blotting with the antibodies indicated to the left of each
panel. (a) H3K18ac and phosphorylated Akt in different cell lines were assessed by
Western blotting. (b) HL-7702 cells were pretreated with IGF (15 ng/ml) for 30 min
before LY294002 (16 lM) treatment for 24 h. (c) HL-7702 cells were treated with or
without 16 lM LY294002 for 24 h. (d) H3K18ac levels were determined in WT and
stable DN-Akt transfectants (HL-7702/DN-Akt). P-GSK3b was used as a control for
Akt activity. (e) Immunoblot analysis of H3K18ac in HL-7702 cells transfected with
control (ctrl) or Akt siRNA for 48 h.
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IgG (Santa Cruz Biotechnology, as a negative control) or primaryFig. 2. Akt interacts with and phosphorylates CBP on Thr1871a, Coimmunoprecipitation
plasmids were immunoprecipitated with antibodies against HA or Myc. Whole cell lysate
of CBP and Akt. (b) Examination of the interaction between endogenous CBP and Akt by im
7702 cells (±LY294002, 16 lM). (c) CBP was immunoprecipitated from HL-7702 cells cotr
to Western blotting analysis with an Akt substrate antibody. (d) HA-tagged Akt was
immunoprecipitated by an antibody against CBP from HL-7702 (±LY294002) or DN-Akt/H
antibody against phospho-CBP. (f) After immunoprecipitation of phosphorylated endogen
blotting with an antibody against CBP. (g) CBP was expressed and immunoprecipitated fro
Western blotting with an antibody against phospho-CBP.antibodies (Santa Cruz Biotechnology) overnight at 4 C. Fifty
microliters of Protein A/G agarose beads was then added, and the
lysates were incubated for another 3 h. The beads were washed 5
times with BC300 buffer and collected via centrifugation. The pre-
cipitated proteins were released by boiling in BC300 buffer and re-
solved by SDS–PAGE (15%).
2.12. Statistical analysis
Statistical analyses were performed with Student’s t-test. A P
value of <0.05 was considered signiﬁcant (⁄P < 0.05 and ⁄⁄P < 0.01).
3. Results and discussion
3.1. Akt inversely regulates H3K18ac
While investigating the differences between the histone acetyl-
transferases CBP and p300, we unexpectedly observed that cells
with high levels of activated, and therefore phosphorylated, Akt
generally had lower levels of H3K18 acetylation (Fig. 1a). This in-
verse correlation prompted us to determine whether Akt activity
affects H3K18 acetylation. Indeed, insulin-like growth factor
(IGF)-induced activation of Akt by phosphorylation decreased
H3 K18 acetylation; this decrease could be rescued by the PI3K-
Akt inhibitor, LY294002 (Fig. 1b, c). Similarly, the expression of
dominant-negative Akt (DN-Akt) [18] (Fig. 1d) or knocking down
Akt expression with small interfering RNA (Fig. 1e) also enhanced
H3K18ac. H3K18ac was further shown to be inversely correlated
with Akt activity over time (Supplementary Fig. 1). Using Western
blotting analyses, we also examined a number of other histone
modiﬁcations, including H3K14ac, H3K9ac, H3K27ac, H3K23acassay of CBP and Akt. Lysates from HL-7702 cells transfected with the indicated
(lysate) was also subjected to Western blotting analysis to examine the expression
munoprecipitation and Western blotting with antibodies against CBP or Akt in HL-
ansfected with Myc-tagged WT-CBP and either CA-Akt or DN-Akt and then subjected
expressed and immunoprecipitated from HL-7702 cells. (e) Endogenous CBP was
L-7702 (stable DN-Akt transfectant) cells and subjected to Western blotting with an
ous CBP by an antibody against phospho-CBP, the lysates were analyzed by Western
m HL-7702 cells transfected with WT (±LY294002) or T1871A-CBP and subjected to
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on these epigenetic modiﬁcations were observed (Supplementary
Fig. 1).
We next investigated how H3K18ac is regulated by Akt signal-
ing. We ﬁrst examined the protein levels of the enzymes that reg-
ulate H3K18ac, including CBP, p300, Gcn5, PCAF and SIRT7 [15,16].
No change was observed following the addition of IGF (Supplemen-
tary Fig. 2). Because a recent study suggested that SIRT7 deacety-
lates H3K18 [16], we examined whether Akt signaling leads to
the recruitment of SIRT7 to its target gene promoters. The tested
genes that exhibited reduced H3K18ac following Akt signaling
exhibited no increase in SIRT7 binding (Supplementary Fig. 2).
Next, we investigated whether HAT activity is affected by Akt
signaling because Akt-mediated phosphorylation of p300 at
Ser1834 is essential for its histone acetyltransferase activity [19].
The preferred Akt consensus motif is RXRXXpS/T, where X is any
amino acid, R is arginine and pS/T is phosphorylated serine or thre-
onine [20]. This motif is not found in Gcn5 or PCAF. Neither expres-
sion of the S1834A-p300 mutation (which cannot be
phosphorylated at this site) nor expression of the S1834E-p300
mutation (which mimics p300 phosphorylation status) had an ef-
fect on H3K18ac (Supplementary Fig. 3).
3.2. Akt interacts with and phosphorylates CBP on Thr1871
Because CBP contains a putative phosphorylation site, Thr1871
(Supplementary Fig. 4), we wondered whether it could be modu-
lated by Akt. To determine whether CBP is a target of Akt, we per-
formed coimmunoprecipitation experiments and detected anFig. 3. Akt suppresses CBP HAT activity. Proteins were detected by Western blotting
cotransfected with CBP and WT-Akt, CA-Akt or DN-Akt plasmids. Samples were collected
cells. Samples were collected after 48 h. (c) DN-Akt/ HL-7702 cells were transfected
cotransfection with FLAG-tagged WT-CBP or the 1871E mutant and HA-DN-Akt or CA-A
mutant of CBP-FLAG were immunopuriﬁed by anti-FLAG antibody or by IgG (control). (e)
FLAG-CBP or the T1871A mutant and incubated in kinase assay buffer for 30 min. HAT
T1871E or T1871A was expressed in vitro and immunopuriﬁed with an anti-FLAG antibassociation between Myc-tagged CBP and hemagglutinin (HA)-
tagged Akt (Fig. 2a). Wild-type (WT)-CBP associated with constitu-
tively activated Akt (CA-Akt) but not DN-Akt. We also observed an
association between endogenous Akt and CBP that was reduced in
cells treated with LY294002 (Fig. 2b; Supplementary Fig. 5), indi-
cating that these two molecules interact in vivo.
To determine whether Akt can phosphorylate CBP, we immuno-
precipitated CBP and probed it with an antibody that recognizes
the phosphorylated form of Akt substrates. The level of CBP phos-
phorylation was 8-fold higher in CA-Akt-expressing cells than in
DN-Akt-expressing cells (Fig. 2c). An in vitro kinase assay also
demonstrated that Akt phosphorylates WT-CBP but not variants
of CBP in which Thr1871 was replaced by Ala or Glu (T1871A and
T1871E, respectively) or by glutathione S-transferase (GST)
(Fig. 2d). To further conﬁrm that Akt phosphorylates CBP at
Thr1871 in vivo, we generated a polyclonal antibody (phosphor-
CBP antibody) that speciﬁcally recognizes a CBP peptide harboring
phosphorylated Thr1871 but fails to detect an unphosphorylated
CBP peptide or an unrelated peptide (Supplementary Fig. 6). This
antibody was used to show that phosphorylation of CBP at
Thr1871 is correlated with the presence of activated, phosphory-
lated Akt in multiple cell lines (Supplementary Fig. 7). To further
investigate whether CBP phosphorylation at Thr1871 is regulated
by Akt, endogenous CBP from untreated or LY294002-treated HL-
7702 cells or DN-Akt/HL-7702 (stable DN-Akt transfectant) cells
was immunoprecipitated and immunoblotted with the phosphor-
CBP antibody (Fig. 2e). CBP phosphorylation was detected in
WT-HL-7702 cells but not in cells treated with LY294002 or in
DN-Akt/HL-7702 cells (Fig. 2e). When the same lysates werewith antibodies as indicated to the left of each panel. (a) HL-7702 cells were
after 48 h. (b) WT or mutant CBP (T1871A, T1871E) was transfected into HL-7702
with control (ctrl) or CBP siRNA. Samples were collected after 48 h. (d) After
kt for 48 h, cells were treated with LY294002 for 1.5 h. Then, the WT and T1871E
HA-CA-Akt immunoprecipitated from unstimulated cell lysates was mixed with WT
activity was then assayed as described in the section 2. (f) FLAG-tagged WT-CBP,
ody. HAT activity was then assayed.
Fig. 4. Akt-mediated phosphorylation of CBP affects substrate afﬁnity. (a) Coimmunoprecipitation of endogenous histone H3 and transfected WT or mutant CBP from HL-
7702 cells. (b) Western blot analysis of soluble (s) and chromatin-bound (c) fractions from cells expressing exogenous WT or mutant CBP. (c and d), Western blot analysis of
endogenous CBP in soluble (s) and chromatin-bound (c) fractions from HL-7702 (±LY294002) and DN-Akt/ HL-7702 cells; (c) or from HL-7702 cells; (d) treated with IGF
(25 ng/ml) or a combination of IGF and LY294002. (e) Genes that are differentially expressed following WT-CBP and T1871A-CBP transfection were determined in HL-7702
cells by microarray analysis. (f) Expression ofMDM2 in response to exogenous expression ofWT or mutant CBP in HL-7702 cells. The values are presented as the mean ± S.E.M.
percentage relative to GAPDH. (g and h) Chromatin immunoprecipitation analysis on the MDM2 promoter with the indicated antibodies was performed with Mef2c as a
negative control in HeLa cells transfected with WT or mutant CBP; (g) in HL-7702 cells (±LY294002, 15 lM) and in DN-Akt stable transfectants (h).
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lowed by Western blotting with a CBP-speciﬁc antibody, we ob-
served that blocking Akt activity decreased the intracellular level
of phosphorylated CBP (Fig. 2f). A similar result was obtained in
HL-7702 cells transiently transfected with WT- or T1871A-CBP
plasmid (mimicking the unphosphorylated state) (Fig. 2g). To-
gether, these results indicate that Akt physically interacts with
CBP and phosphorylates it at Thr1871 in vivo.
3.3. Akt suppresses CBP HAT activity
Next, we examined whether the Akt-mediated phosphorylation
of CBP inhibits the acetylation of H3K18. We observed that DN-Akt
enhanced H3 K18ac, while CA-Akt suppressed it (Fig. 3a). Similar
results were obtained by immunoﬂuorescence analysis of
H3K18ac in transfected HL-7702 cells (Supplementary Fig. 8).
The H3K18ac level was 3- to 5-fold higher in cells transfected with
T1871A-CBP than in cells transfected with WT- or T1871E-CBP
(mimicking the phosphorylated state) (Fig. 3b). Moreover, DN-
Akt was unable to enhance H3K18Ac levels upon knockdown of
CBP by siRNA (Fig. 3c). Thus, the phosphorylation of CBP at
Thr1871 by Akt decreases H3K18ac.
To further investigate whether this phenomenon is due to an
alteration of HAT activity after phosphorylation of CBP by Akt, we
performed in vitro HAT activity assays. First, we examined whether
the dephosphorylation of Thr-1871 increased the intrinsic HAT
activity of CBP. FLAG-tagged WT-CBP or T1871E-CBP mutant
cotransfected with HA-CA-Akt or DN-Akt was immunoprecipitatedwith an anti-FLAG antibody. HAT activitywas assayed bymeasuring
the acetylation of H3K18. As shown in Fig. 3d, WT-CBP but not the
T1871Emutant acetylatedH3K18 in response to LY294002 stimula-
tion (Fig. 3d, lanes 1–4), and this effect was inhibited by CA-Akt
(Fig. 3d, lanes 7 and 8). DN-Akt enhanced the acetylation of H3K18
induced by WT-CBP (compare lanes 6 and 4) but not that induced
by the T1871Emutant (Fig. 3d, compare lanes 5 and 2). These results
demonstrate that phosphorylation of CBP at Thr1871 inhibits its
intrinsicHAT activity. To further demonstrate that the phosphoryla-
tion of Thr1871 by Akt inhibits HAT activity, WT-CBP or the T1871A
mutant extracted by FLAG immunoprecipitation was mixed with
CA-Akt extracted by HA tag from unstimulated cell lysates and sub-
jected to in vitro phosphorylation andHAT activity assays. As shown
in Fig 3e, increased phosphorylation and decreased HAT activity
were observed for WT-CBP but not the T1871A mutation (Fig. 3e).
To conﬁrm this ﬁnding, CBP was expressed in vitro and subjected
to a HAT activity assay. As shown in Fig 3f, H3K18 was acetylated
by WT-CBP, and this effect was enhanced by the T1871A mutant
but attenuated by the T1871E mutant (Fig. 3f). These data clearly
demonstrate that Akt phosphorylation of CBP at Thr1871 is critical
for the regulation of intrinsic HAT activity.
3.4. Akt-mediated phosphorylation of CBP changes substrate afﬁnity
To examinewhether phosphorylation alters the afﬁnity of CBP for
its substrate, histone H3, we performed coimmunoprecipitation as-
says of histone H3 and CBP. The association of T1871A-CBP with H3
was 2- to 4-fold greater than that of WT-CBP or T1871E-CBP with
Fig. 5. Phosphorylation of CBP at Thr1871 by Akt enhances its oncogenic activities. HL-7702 cells were transiently transfected with EGFP-vector, WT CBP plasmid or mutant
EGFP-CBP plasmid and subsequently sorted by FACS analysis. (a), The amount of cell proliferation was evaluated by MTT assay. (b) The soft-agar colony formation assay, as
described in the Section 2. (c) The Transwell–migration assay, as described in the Materials and Methods. (d) MDA-MB453 cells transfected with vector, WT CBP or mutant
CBP were injected into the mammary fat pads of nude mice. The expression ofMDM2 in response to the transfected genes was analyzed by real time-PCR in Fig. 4f before the
cells were inoculated into the mammary fat pads. The tumor volume was measured at the indicated times.
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andWT-CBP (Fig. 4a). Thus, CBPT1871 phosphorylation indeedaffected
the afﬁnity of CBP for H3. In addition, we isolated soluble and insolu-
ble (chromatin-bound) nuclear fractions from HL-7702 cells that
were transfected withWT-CBP ormutant CBP. T1871A-CBP predom-
inantly existed in an insoluble nuclear fraction, suggesting that it
strongly associates with chromatin (Fig. 4b). We further investigated
the chromatin association of endogenous CBP in cells in which Akt
activity was either induced or blocked. Blockage of Akt consistently
increased the chromatin-bound CBP, whereas Akt activation had
the opposite effect (Fig. 4c and d; Supplementary Fig. 9).
Aberrant changes in H3K18ac and Akt signaling have been
reported in a variety of human cancers [12,21]. A low level of
H3K18ac has been observed in cancers of poorer prognostic
subtypes [12]. To determinewhether the CBPphosphorylationmed-
iated byAkt is functionally important, particularly in tumorigenesis,
we examined the inﬂuence of CBP phosphorylation on gene expres-
sion. We performed microarray analysis with total RNA isolated
from HL-7702 cells expressing WT-CBP or T1871A-CBP (Fig. 4e).
The expression of T1871A-CBP altered the transcription of more
than 200 genes (Table 1). Among the affected genes, nearly four-
ﬁfthswere down-regulated. The altered transcription of these genes
was also conﬁrmed by real-time PCR (Supplementary Fig. 10).
Certain genes that are affectedbyT1871A-CBPare known tobe asso-
ciated with tumor progression. PCR analysis revealed that the
expression ofMDM2, a knownproto-oncogene [22], was suppressed
by T1871A-CBP (Fig. 4f), consistent with the high level of H3K18ac
on the MDM2 promoter (Fig. 4g). This phenomenon was also ob-
served in HL-7702 cells treated with LY294002 or in DN-Akt stable
transfectants (Fig. 4h).
To further demonstrate that the CBP phosphorylation
mediated by Akt is functionally involved in Akt-induced tumorigen-
esis, we next performed MTT, Soft-Agar Colony Formation and
Transwell-Migration assays on cells sorted by ﬂuorescence-
activated cell sorting (FACS) that were transfected with WT ormutant CBP. Compared with the results for the vector control,
T1871E and (to a lesser degree)WT-CBP enhanced cell proliferation
and migration (Fig. 5a–c); by contrast, T1871A-CBP suppressed cell
proliferation and migration (Fig. 5a–c). To test the effect of the
Akt-mediated phosphorylation of CBP on tumorigenicity in vivo,
we injected the mammary fat pad of nude mice with nontumori-
genic MDA-MB453 cells transfected with WT-CBP or mutant CBP.
The tumor growth induced by T1871E-CBPwasmore dramatic than
the growth induced by WT-CBP, but the vector and T1871A did not
promote tumor formation (Fig. 5d), suggesting that the phosphory-
lation of CBP at Thr1871 by Akt enhances its oncogenic activities and
that the acetylation of H3K18 could be involved in oncogenic signal
transduction.
Our studydemonstrates that theHATactivity ofCBP responsible for
H3K18ac is regulated by the Akt signaling pathway through the phos-
phorylation of CBP on Thr1871. The phosphorylation of CBP suppresses
the acetylation of H3K18 and disrupts gene silencing and thus may
contribute to oncogenesis. Furthermore, P-CBPThr1871 enhances cell
growth in culture and tumordevelopment in animals, andP-CBPThr1871
also correlates with breast premalignant lesions and breast cancer
(Supplementary Fig. 11 and Text). Thus, these modiﬁcations could be
developed into molecular target to diagnose cancer.
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